Press release
Facioscapulohumeral Muscular Dystrophy Pipeline 2024 | Fulcrum Therapeutics, Dyne Therapeutics, Hoffmann-La Roche, aTyr Pharma, Inc., Avidity Biosciences, Inc.
Discover the latest drugs and treatment options in the Facioscapulohumeral Muscular Dystrophy Pipeline. Dive into DelveInsight's comprehensive report today! @ Facioscapulohumeral Muscular Dystrophy Pipeline Outlook [https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Facioscapulohumeral Muscular Dystrophy Pipeline Report
* July 2024:- Hoffmann-La Roche - A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Pharmacodynamics, Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy.
* DelveInsight's Facioscapulohumeral Muscular Dystrophy pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Facioscapulohumeral Muscular Dystrophy treatment.
* The leading Facioscapulohumeral Muscular Dystrophy Companies such as Fulcrum Therapeutics, Dyne Therapeutics, Hoffmann-La Roche, aTyr Pharma, Inc., Avidity Biosciences, Inc. , and others.
* Promising Facioscapulohumeral Muscular Dystrophy Therapies such as Losmapimod, RO7204239, AOC 1020 , and others.
Stay ahead with the most recent pipeline outlook for Facioscapulohumeral Muscular Dystrophy. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Facioscapulohumeral Muscular Dystrophy Treatment Drugs [https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Facioscapulohumeral Muscular Dystrophy Emerging Drugs Profile
* Losmapimod: Fulcrum Therapeutics
Losmapimod is an investigational, selective p38/ mitogen activated protein kinase (MAPK) inhibitor. Fulcrum exclusively in-licensed losmapimod from GSK following Fulcrum's discovery of the role of p38/ inhibitors in the reduction of DUX4 expression and an extensive review of known compounds. Results reported from the ReDUX4 trial demonstrated slowed disease progression and improved function, including positive impacts on upper extremity strength, supporting losmapimod's potential to be a transformative therapy for the treatment of FSHD. Although losmapimod had never previously been explored in muscular dystrophies, it had been evaluated in more than 3,600 subjects in clinical trials across multiple other indications, with no safety signals attributed to losmapimod.
* DYNE-301: Dyne Therapeutics
DYNE-301 is a DUX4L1 protein expression stimulant, which consists of company's proprietary Fab conjugated with our linker to an ASO that is designed to address the genetic basis of FSHD by reducing DUX4 expression in muscle tissue. Proof-of-concept data showing that DYNE-301 reduced expression of key DUX4 biomarkers in FSHD patient myotubes, a type of muscle cell. Currently the product is in preclinical stage of development for the disease.
Explore groundbreaking therapies and clinical trials in the Facioscapulohumeral Muscular Dystrophy Pipeline. Access DelveInsight's detailed report now! @ New Facioscapulohumeral Muscular Dystrophy Drugs [https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Facioscapulohumeral Muscular Dystrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal
Facioscapulohumeral Muscular Dystrophy Products have been categorized under various Molecule types such as
* Oligonucleotide
* Peptide
* Small molecule
Unveil the future of Facioscapulohumeral Muscular Dystrophy Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Facioscapulohumeral Muscular Dystrophy Market Drivers and Barriers [https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Facioscapulohumeral Muscular Dystrophy Pipeline Report
* Coverage- Global
* Facioscapulohumeral Muscular Dystrophy Companies- Fulcrum Therapeutics, Dyne Therapeutics, Hoffmann-La Roche, aTyr Pharma, Inc., Avidity Biosciences, Inc., and others.
* Facioscapulohumeral Muscular Dystrophy Therapies- Losmapimod, RO7204239, AOC 1020, and others.
* Facioscapulohumeral Muscular Dystrophy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Facioscapulohumeral Muscular Dystrophy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Facioscapulohumeral Muscular Dystrophy Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Facioscapulohumeral Muscular Dystrophy Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Facioscapulohumeral Muscular Dystrophy: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Facioscapulohumeral Muscular Dystrophy- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Losmapimod: Fulcrum Therapeutics
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* DYNE-301: Dyne Therapeutics
* Drug profiles in the detailed report.....
* Inactive Products
* Facioscapulohumeral Muscular Dystrophy Key Companies
* Facioscapulohumeral Muscular Dystrophy Key Products
* Facioscapulohumeral Muscular Dystrophy- Unmet Needs
* Facioscapulohumeral Muscular Dystrophy- Market Drivers and Barriers
* Facioscapulohumeral Muscular Dystrophy- Future Perspectives and Conclusion
* Facioscapulohumeral Muscular Dystrophy Analyst Views
* Facioscapulohumeral Muscular Dystrophy Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=facioscapulohumeral-muscular-dystrophy-pipeline-2024-fulcrum-therapeutics-dyne-therapeutics-hoffmannla-roche-atyr-pharma-inc-avidity-biosciences-inc]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Facioscapulohumeral Muscular Dystrophy Pipeline 2024 | Fulcrum Therapeutics, Dyne Therapeutics, Hoffmann-La Roche, aTyr Pharma, Inc., Avidity Biosciences, Inc. here
News-ID: 3611317 • Views: …
More Releases from ABNewswire
AI and the Future of the Translation Profession - Translation Conference to Deli …
Want to work smarter with AI - not just "go with the flow"? At the conference we'll share tools, methods, and practical workflows from the field - not just theory. Upgrade your professional toolkit.
The 2026 ITA hybrid translation conference will focus on one of the most urgent needs of today's language professionals: practical, applicable knowledge for working effectively - and responsibly - with artificial intelligence in real-world translation environments.
While public…
Caliente Brands Brings Bold Heat to Premium Beef Jerky Market with Authentic Spi …
Caliente Brands, LLC launches CalienteJerky.com, offering hickory-smoked beef jerky crafted exclusively from 100% USDA Approved Beef with uniquely spicy flavor profiles. The veteran-owned company targets consumers seeking bold, adventurous snack options with flavors ranging from Spicy Peppered to innovative Spicy Birria, delivering what the brand promises: where smoky and spicy meet delicious.
Caliente Brands, LLC has officially entered the premium beef jerky market with a clear mission: to deliver authentic spicy…
Patio Elegance Expands Luxury Collection to Create the Ultimate High-End Outdoor …
Patio Elegance announces an expanded portfolio of premium outdoor living solutions, ranging from professional-grade kitchen islands and grills to advanced wellness installations like cold plunges, jacuzzis, and handcrafted saunas. This comprehensive collection allows homeowners to design fully integrated, resort-style environments focused on culinary excellence, restorative wellness, and sophisticated comfort.
Patio Elegance is transforming how affluent homeowners approach outdoor living by offering a complete suite of luxury products that turn ordinary backyards…
DallasFortWorthInsurance.com Launches as the Premier Online Destination for DFW …
DallasFortWorthInsurance.com, a new venture from the trusted Baxter Insurance Agency, Inc., is now live, offering a comprehensive platform for Dallas-Fort Worth residents to easily compare and secure the best rates on auto, home, and life insurance.
DALLAS-FORT WORTH, TX - Jan 10, 2026 - Baxter Insurance Agency, Inc., a cornerstone of the Texas insurance community for over four decades, is proud to announce the launch of its latest website, DallasFortWorthInsurance.com. This…
More Releases for Facioscapulohumeral
Facioscapulohumeral Muscular Dystrophy Clinical Trial Pipeline Shows Potential w …
DelveInsight's "Facioscapulohumeral Muscular Dystrophy Pipeline Insight 2025" report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in the Facioscapulohumeral Muscular Dystrophy pipeline landscape. It covers the Facioscapulohumeral Muscular Dystrophy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Facioscapulohumeral Muscular Dystrophy therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the…
Facioscapulohumeral Muscular Dystrophy (FSHD) Market is projected to reach USD 4 …
The global Facioscapulohumeral Muscular Dystrophy (FSHD) Market was valued at USD 210 million in 2024 and is projected to reach USD 482 million by 2034, expanding at a CAGR of 8.6% during the forecast period (2025-2034). The market is driven by rising diagnosis rates, advancements in genetic testing, improved clinical awareness among neuromuscular specialists, and accelerating drug development targeting the underlying molecular mechanisms of FSHD.
Download Full PDF Sample Copy of…
Facioscapulohumeral Muscular Dystrophy (FSHD) Market Massive Growth opportunity …
Introduction
Facioscapulohumeral muscular dystrophy (FSHD) is a rare genetic muscle disorder characterized by progressive weakness of facial, shoulder, and upper arm muscles, and eventually lower body muscles. It is the third most common type of muscular dystrophy, affecting approximately 1 in 8,000 to 1 in 20,000 individuals worldwide.
FSHD is typically caused by abnormal expression of the DUX4 gene due to genetic mutations on chromosome 4. While there is currently no approved…
Facioscapulohumeral Muscular Dystrophy Market Expected to Evolve Through 2034 Am …
Facioscapulohumeral Muscular Dystrophy (FSHD) is one of the most prevalent forms of muscular dystrophy, characterized by progressive skeletal muscle weakness that initially affects the face, shoulders, and upper arms. The condition is genetically linked to abnormal expression of the DUX4 gene, most commonly caused by contraction of the D4Z4 repeat on chromosome 4. FSHD can significantly impact mobility, quality of life, and daily function, though disease progression varies widely among…
Facioscapulohumeral Muscular Dystrophy Clinical Trials, Treatment Drugs, Pipelin …
DelveInsight's, "Facioscapulohumeral Muscular Dystrophy Pipeline Insight 2024" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Facioscapulohumeral Muscular Dystrophy pipeline landscape. It covers the Facioscapulohumeral Muscular Dystrophy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Facioscapulohumeral Muscular Dystrophy therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Facioscapulohumeral Muscular Dystrophy pipeline products in this…
Facioscapulohumeral Muscular Dystrophy Market Size, Share, Trends, Demand, Growt …
Global Facioscapulohumeral Muscular Dystrophy Market study by Data Bridge Market Research provides details about the market dynamics affecting the Facioscapulohumeral Muscular Dystrophy market, Market scope, Market segmentation and overlays shadow upon the leading market players highlighting the favourable competitive landscape and trends prevailing over the years.
A number of estimations and calculations have been included in the first class Facioscapulohumeral Muscular Dystrophy market report by assuming definite base year and the…
